Pfizer's General Counsel Amy Schulman

Say hello to Pfizer's new general counsel, Amy Schulman, a top litigator who's served as lead attorney on the company's Celebrex and Bextra cases. A partner at DLA Piper, Schulman specializes in defending companies against big product liability lawsuits. She's a top producer for that firm who earned $5.75 million last year. Schulman, 47, replaces Allen Waxman, who left Pfizer in March for personal reasons; she'll report directly to CEO Jeff Kindler (photo), who's also a lawyer.
Related Articles:
Pfizer taps litigator as new GC
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
